- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07645105
Body Weight Reduction and Metabolic/Biochemical Parameters in Overweight or Obesity
The Effect of Body Weight Reduction on Selected Metabolic and Biochemical Parameters in Individuals With Overweight or Obesity
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
This was a single-center prospective observational cohort study conducted at the Medical University of Silesia in Katowice, Poland, and in a metabolic outpatient clinic in Miasteczko Śląskie, Poland. The study was designed to evaluate the effect of body weight reduction on selected metabolic, biochemical, oxidative-stress, inflammatory, and body-composition parameters in individuals with overweight or obesity.
The study was conducted in the context of routine metabolic outpatient care. Participants with overweight or obesity received standard lifestyle-based body weight reduction management, including individualized dietary recommendations, physical-activity guidance, health education, and regular follow-up visits. The investigators did not assign participants to an investigational medicinal product, medical device, dietary supplement, surgical procedure, pharmacological intervention, or experimental therapy. The study prospectively observed participants receiving routine lifestyle-based weight reduction management and assessed changes in clinical and laboratory parameters before and after body weight reduction.
The approved study protocol planned the inclusion of individuals with overweight or obesity and a normal-weight comparison group. Participants with BMI > 25 kg/m² were evaluated in relation to body weight reduction, while individuals with normal body weight served as a comparison group for selected baseline analyses. Patients with overweight or obesity were assessed by medical examination, dietary and clinical questionnaires, anthropometric measurements, body-composition analysis, and fasting blood sampling. Body-composition analysis included assessment of body weight, fat mass, fat-free mass, skeletal muscle mass, total body water, visceral fat, and related parameters. Blood samples were collected for biochemical analyses, including markers of glucose metabolism, lipid metabolism, oxidative stress, antioxidant status, inflammatory markers, adipokines, cytokines, chemokines, growth factors, and selected cardiovascular-risk parameters.
Participants with overweight or obesity were followed during standard body weight reduction management until clinically relevant weight reduction or achievement of optimal body weight. According to the original study documentation, assessments were planned before the start of weight reduction, after approximately 10% body weight reduction, and after approximately 20% body weight reduction or achievement of target body weight. Follow-up visits included body weight measurements, waist and hip circumference measurements, dietary counselling, education regarding caloric intake, and motivation to continue lifestyle modification.
The primary objective of the study was to assess whether body weight reduction in individuals with overweight or obesity is associated with changes in selected metabolic and biochemical parameters. Secondary objectives included evaluation of oxidative-stress and antioxidant-status parameters, glucose and lipid metabolism, inflammatory markers, adipokines, cytokines, and body-composition changes. The study also aimed to assess relationships between biochemical parameters and body-composition indices before and after body weight reduction.
The study was approved by the Bioethics Committee of the Medical University of Silesia in Katowice, Poland. All participants received information about the study and provided written informed consent before participation. This ClinicalTrials.gov record is submitted retrospectively to meet journal publication requirements and to provide transparent public information about the completed study.
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
Silesian Voivodeship
-
Miasteczko Śląskie, Silesian Voivodeship, Polsko, 42-610
- Eko-Prof-Med Medical Center, Metabolic Outpatient Clinic
-
Zabrze, Silesian Voivodeship, Polsko, 41-808
- Department of Biochemistry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Adults aged 18-85 years
- BMI > 25 kg/m²
- Overweight or obesity diagnosed on the basis of medical examination and body-composition assessment
- Participation in routine lifestyle-based body weight reduction management in a metabolic outpatient clinic
- Written informed consent to participate in the study
Exclusion Criteria:
- Lack of informed consent
- Severe hepatic insufficiency
- Severe renal insufficiency
- Severe respiratory insufficiency
- Severe circulatory insufficiency
- Disturbances of consciousness
- Treatment-resistant depression
- Chronic alcohol abuse
- Pregnancy
- History of serious nervous system injury
- Implanted cardiac pacemaker
- Pharmacological treatment affecting glucose and/or lipid metabolism
- Incomplete follow-up or incomplete laboratory data
Studijní plán
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
Individuals With Overweight or Obesity
Adults with BMI > 25 kg/m² who were receiving routine lifestyle-based body weight reduction management in a metabolic outpatient clinic.
Participants were prospectively observed and assessed before and after body weight reduction.
Assessments included clinical and dietary questionnaires, anthropometric measurements, body-composition analysis, fasting blood sampling, and biochemical, metabolic, oxidative-stress, inflammatory, adipokine, and cytokine measurements.
|
Standard lifestyle-based body weight reduction management received as part of routine metabolic outpatient care.
It included individualized dietary recommendations, physical-activity guidance, health education, and regular follow-up visits.
Participants were not assigned to this management as part of the study; the study prospectively observed patients receiving routine care and assessed metabolic, biochemical, inflammatory, oxidative-stress, adipokine, cytokine, and body-composition parameters before and after body weight reduction.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in Body Weight
Časové okno: Baseline and after body weight reduction, up to approximately 6 months
|
Change in body weight from baseline to follow-up after routine lifestyle-based body weight reduction management.
|
Baseline and after body weight reduction, up to approximately 6 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in Body Fat Mass
Časové okno: Baseline and after body weight reduction, up to approximately 6 months
|
Change in body fat mass assessed by bioelectrical impedance analysis and expressed in kilograms.
|
Baseline and after body weight reduction, up to approximately 6 months
|
|
Change in Glucose concentration in mg/dl.
Časové okno: Baseline and after body weight reduction, up to approximately 6 months
|
Changes in fasting glucose.
|
Baseline and after body weight reduction, up to approximately 6 months
|
|
Change in total-cholesterol concentration in mg/dl.
Časové okno: Baseline and after body weight reduction, up to approximately 6 months
|
Changes in total cholesterol concentration.
|
Baseline and after body weight reduction, up to approximately 6 months
|
|
Change in malondialdehyde concentration in μmol/l.
Časové okno: Baseline and after body weight reduction, up to approximately 6 months
|
Change in blood malondialdehyde concentration, assessed as a marker of lipid peroxidation and oxidative stress, from baseline to follow-up after body weight reduction.
|
Baseline and after body weight reduction, up to approximately 6 months
|
|
Change in serum IL-6 concentration in pg/ml.
Časové okno: Baseline and after body weight reduction, up to approximately 6 months
|
Change in serum interleukin-6 (IL-6) concentration from baseline to follow-up after body weight reduction.
IL-6 was measured in serum samples as a marker of systemic low-grade inflammation and expressed in pg/ml.
|
Baseline and after body weight reduction, up to approximately 6 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Sławomir Kasperczyk, Prof, Medical University of Silesia in Katowice
Publikace a užitečné odkazy
Obecné publikace
- Szlachta B, Birkova A, Cizmarova B, Glogowska-Gruszka A, Zalejska-Fiolka P, Dydon M, Zalejska-Fiolka J. Erythrocyte Oxidative Status in People with Obesity: Relation to Tissue Losses, Glucose Levels, and Weight Reduction. Antioxidants (Basel). 2024 Aug 7;13(8):960. doi: 10.3390/antiox13080960.
- Szlachta B, Birkova A, Wielkoszynski T, Gospodarczyk A, Hubkova B, Dydon M, Zalejska-Fiolka J. Serum Oxidative Status in People with Obesity: Relation to Tissue Losses, Glucose Levels, and Weight Reduction. Antioxidants (Basel). 2023 Oct 27;12(11):1923. doi: 10.3390/antiox12111923.
- Zalejska-Fiolka J, Birkova A, Hubkova B, Wielkoszynski T, Cizmarova B, Szlachta B, Fiolka R, Blaszczyk U, Wylegala A, Kasperczyk S, Grzanka A, Marekova M, Toborek M. Successful correction of hyperglycemia is critical for weight loss and a decrease in cardiovascular risk in obese patients. J Nutr Biochem. 2022 Aug;106:109021. doi: 10.1016/j.jnutbio.2022.109021. Epub 2022 Apr 25.
- Zalejska-Fiolka J, Birkova A, Wielkoszynski T, Hubkova B, Szlachta B, Fiolka R, Blaszczyk U, Kuzan A, Gamian A, Marekova M, Toborek M. Loss of Skeletal Muscle Mass and Intracellular Water as Undesired Outcomes of Weight Reduction in Obese Hyperglycemic Women: A Short-Term Longitudinal Study. Int J Environ Res Public Health. 2022 Jan 17;19(2):1001. doi: 10.3390/ijerph19021001.
- Zalejska-Fiolka J, Hubkova B, Birkova A, Velika B, Puchalska B, Kasperczyk S, Blaszczyk U, Fiolka R, Bozek A, Maksym B, Marekova M, Birkner E. Prognostic Value of the Modified Atherogenic Index of Plasma during Body Mass Reduction in Polish Obese/Overweight People. Int J Environ Res Public Health. 2018 Dec 27;16(1):68. doi: 10.3390/ijerph16010068.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Poruchy výživy
- Metabolické choroby
- Nadměrná výživa
- Tělesná hmotnost
- Poruchy metabolismu glukózy
- Rezistence na inzulín
- Hyperinzulinismus
- Patologické stavy, příznaky a symptomy
- Nutriční a metabolické nemoci
- Příznaky a symptomy
- Nadváha
- Obezita
- Metabolický syndrom
- Obezita, břicho
- Abdominal obesity metabolic syndrome
Další identifikační čísla studie
- KNW/0022/KB1/19/I/16
- Secondary ID: KNW-1-016/N/7/2 (Jiné číslo grantu/financování: Medical University of Silesia)
- Secondary ID: KNW-1/109/K/8/Z (Jiný identifikátor: Medical University of Silesia)
- Secondary ID: KNW-1/171/K/9/O (Jiný identifikátor: Medical University of Silesia)
- Secondary ID: PCN-1-049/K/0/O (Jiný identifikátor: Medical University of Silesia)
- Secondary ID: PCN-1-018/K/1/O (Jiný identifikátor: Medical University of Silesia)
- Secondary ID: PCN-1-132/K/2/O (Jiný identifikátor: Medical University of Silesia)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .